HowShorted

How shorted is Gain Therapeutics, Inc.?

More shorted than 69% of the 2,877 ranked US companies

7.36%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
−1.05
5 reports (~10 weeks)
−0.05
Aggregate net short position time series for Gain Therapeutics, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 20267.36%−1.05
15 Jul 20268.41%−0.05
30 Jun 20268.46%−0.61
15 Jun 20269.07%+1.57
29 May 20267.50%+0.09
15 May 20267.41%−0.66
30 Apr 20268.07%−1.16
15 Apr 20269.23%+0.14
31 Mar 20269.09%+1.13
13 Mar 20267.96%−0.03
27 Feb 20267.99%−0.43
13 Feb 20268.42%+0.17
30 Jan 20268.25%+1.37
15 Jan 20266.88%−0.51
31 Dec 20257.39%+1.65
15 Dec 20255.74%+2.25
28 Nov 20253.49%−1.44
14 Nov 20254.93%+2.41
31 Oct 20252.52%+1.35
30 Sep 20251.17%+0.12
15 Sep 20251.05%+0.40
29 Aug 20250.65%+0.06
15 Aug 20250.59%−0.09
31 Jul 20250.68%–

Frequently asked questions

How shorted is Gain Therapeutics, Inc. right now?
7.36% of Gain Therapeutics, Inc.'s (GANX) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.